Почетна › Рак дојке › Вирџинија › Richmond
Kliničke studije za Рак дојке u gradu Richmond, VA
27 studija za Рак дојке traži učesnike na lokacijama u gradu Richmond i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Тражи се учесникФаза 3
- Virginia Cancer Institute, Richmond
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Тражи се учесникФаза 3
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian · 11 ми удаљено
The Vanguard Study: Testing a New Way to Screen for Cancer
Тражи се учесникЗдраве особе су добродошле
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
E-Mindfulness Approaches for Living After Breast Cancer
Тражи се учесникФаза 3
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Virginia Cancer Institute, Richmond
- и још 4
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- и још 3
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Тражи се учесникОпсервациона студија
- VCU Massey Cancer Center at Stony Point, Richmond
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Distance-Based Exercise to Preserve Function and Prevent Disability
Тражи се учесник
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Memorial Regional Medical Center, Mechanicsville · 6 ми удаљено
- Bon Secours Saint Francis Medical Center, Midlothian · 11 ми удаљено
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Тражи се учесникФаза 3
- Bon Secours Richmond Community Hospital, Richmond
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- и још 4
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Тражи се учесникФаза 3
- Bon Secours Cancer Institute at St. Mary's, Richmond
- Bon Secours Cancer Institute at Memorial Regional, Mechanicsville · 6 ми удаљено
- Bon Secours St. Francis Medical Center, Midlothian · 11 ми удаљено
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Тражи се учесникОпсервациона студија
- VCU Massey Comprehensive Cancer Center, Richmond
- Bon Secours Cancer Institute at St. Francis, Midlothian · 11 ми удаљено
Single FrAction Interstitial BreaSt BracHytherApy
Тражи се учесникФаза 2
- Virginia Commonwealth University, Richmond
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Тражи се учесникФаза 3
- Research Site, Midlothian · 11 ми удаљено
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Тражи се учесникФаза 3
- Bon Secours Cancer Institute at St. Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Memorial Regional Medical Center, Mechanicsville · 6 ми удаљено
- Bon Secours St. Francis Medical Center, Midlothian · 11 ми удаљено
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Тражи се учесникФаза 3
- VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
- Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian · 11 ми удаљено
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Тражи се учесникФаза 3
- Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 ми удаљено
Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
Тражи се учесник
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Тражи се учесникФаза 2
- Virginia Cancer Institute, Richmond
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Тражи се учесникФаза 3
- Research Site, Midlothian · 11 ми удаљено
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Тражи се учесникФаза 3
- Clinical Trial Site, Midlothian · 11 ми удаљено
Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
Тражи се учесник
- Adult Outpatient Pavilion, Richmond
- Cellular Immunotherapies and Transplant Department, Richmond
- VCU Health at Stony Point, Richmond
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Тражи се учесникФаза 2/3
- Bon Secours St. Francis Medical Center, Midlothian · 11 ми удаљено
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Тражи се учесник
- Virgina Community University Massey Comprehensive Cancer Center, Richmond
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Тражи се учесникФаза 1
- Virginia Commonwealth University, Richmond
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Тражи се учесникФаза 3
- Virginia Commonwealth University, Richmond
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Тражи се учесникФаза 3
- Bon Secours Saint Mary's Hospital, Richmond
- Bon Secours Cancer Institute at Reynolds Crossing, Richmond
- Bon Secours Memorial Regional Medical Center, Mechanicsville · 6 ми удаљено
- и још 1
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Тражи се учесникОпсервациона студија
- VCU Massey Comprehensive Cancer Center, Richmond
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Тражи се учесникФаза 2
- Virginia Commonwealth University, Richmond
Studije za Рак дојке u drugim gradovima
- New York City, NY144 студија
- Houston, TX126 студија
- Boston, MA110 студија
- Nashville, TN78 студија
- Los Angeles, CA73 студија
- Edison, NJ70 студија
- Queens, NY67 студија
- Durham, NC63 студија
- St. Louis, MO63 студија
- Chicago, IL59 студија
- Dallas, TX54 студија
- Philadelphia, PA51 студија
Ostale studije u gradu Richmond
- Немалоклетни карцином плућа26 студија
- Рак простате19 студија
- Затајење срца17 студија
- Рак плућа15 студија
- Кардиоваскуларне болести13 студија
- Плоскоклеточни карцином главе и врата13 студија
- Колоректални карцином13 студија
- Рак (све врсте)12 студија
- Метастатски карцином12 студија
- Difuzni veliki B-ćelijski limfom11 студија
- Steatotna bolest jetre11 студија
- Меланом11 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.